
TORONTO, Nov. 3 /CNW/ - Patheon Inc. (TSX: PTI) today announced that it will be proceeding to put in place new credit facilities in the aggregate amount of $290 million to refinance existing debt of Patheon Inc. and its U.S. subsidiaries including its subsidiaries in Puerto Rico. The new facilities will replace (i) existing credit facilities that are available to the Company's North American operations including those that were established at the time of the acquisition of MOVA Pharmaceutical Corporation in December 2004, and (ii) debt of MOVA Pharmaceutical Corporation and its affiliates in Puerto Rico that was assumed at the time of the acquisition by Patheon. (All amounts are in U.S. dollars unless otherwise indicated.) The new credit facilities will comprise a revolving facility in the amount of $75 million and two term loans in the aggregate amount of $215 million. The term loans will consist of a five-year term loan in the amount of $65 million and a six-year term loan in the amount of $150 million. The new facilities will be secured by the North American assets of Patheon and its subsidiaries, including those in Puerto Rico. The Company has engaged Royal Bank of Canada and RBC Capital Markets as Lead Arranger to syndicate these new credit facilities to a group of financial institutions in Canada and the United States. The refinancing is expected to close in December 2005. Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of 180 pharmaceutical and biotechnology companies. This news release contains forward-looking statements with respect to Patheon, including its business operations and strategy and financial performance and condition. Although management believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from expectations include, but are not limited to, currency fluctuations, the level of outsourcing services required by the pharmaceutical companies (and in particular our clients), the impact of changes in pharmaceutical development and manufacturing regulations and general economic and market factors (including inflation and changes in laws) and other factors discussed in materials filed with applicable securities regulatory authorities from time to time. %SEDAR: 00001700E